{
    "clinical_study": {
        "@rank": "159906", 
        "arm_group": [
            {
                "arm_group_label": "Combizym", 
                "arm_group_type": "Active Comparator", 
                "description": "These patients who have cutted colon polyps will eat the digestion enzyme(Combizym) regularly."
            }, 
            {
                "arm_group_label": "Bifidobacteri", 
                "arm_group_type": "Active Comparator", 
                "description": "These patients who have cutted colon polyps will eat Bifidobacteri regularly"
            }, 
            {
                "arm_group_label": "Combizym + Bifidobacteri", 
                "arm_group_type": "Active Comparator", 
                "description": "These patients who have cutted colon polyps will eat drugs (Combizym + Bifidobacteri) regularly"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Active Comparator", 
                "description": "these patients who have cutted colon polyps will not eat any drugs"
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis is whether digestion enzyme(Combizym) and intestinal flora\n      drugs(Bifidobacteria) can decease recurrence rate of colon polyps"
        }, 
        "brief_title": "The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Combizym", 
            "Bifidobacteri", 
            "Colon Polyps"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colonic Polyps", 
                "Polyps", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Colon polyps has high recurrence rate in the digestion diseases. However, the reasons are\n      not clear. The possible reasons for the recurrence of colon polyps include intestinal\n      inflammation (e.g., Ulcerative colitis), intestinal flora imbalance (the benefit intestinal\n      bacteria reduced, which lead to diarrhea or constipation), long-term indigestion. The\n      investigators propose to examine whether digestion enzyme (Combizym) and intestinal flora\n      drugs(Bifidobacteria) can decease recurrence rate of colon polyps"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients who have cutted colon polyps in one month, and the diagnosis were proved by\n        pathological analysis\n\n        Exclusion Criteria:\n\n          -  have organic or other functional disease\n\n          -  pregnant or breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097394", 
            "org_study_id": "RJYYXHNK-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combizym", 
                "description": "Combizym( 1 tablet, po, tid)", 
                "intervention_name": "Combizym", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Oryz-Aspergillus Enzyme And Pancreatin Tablet", 
                    "(produced by Nordmark Arzneimittel GmbH & Co. KG)"
                ]
            }, 
            {
                "arm_group_label": "Bifidobacteri", 
                "description": "Bifidobacteri (2 tablet, po, tid)", 
                "intervention_name": "Bifidobacteri", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Live Combined Bifidobacterium\uff0cLactobac and Enterococcus Capsules", 
                    "(produced by Shanghai XinYi Company)"
                ]
            }, 
            {
                "arm_group_label": "Combizym + Bifidobacteri", 
                "description": "Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)", 
                "intervention_name": "Combizym + Bifidobacteri", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Combizym(Oryz-Aspergillus Enzyme And Pancreatin Tablet)", 
                    "(produced by Nordmark Arzneimittel GmbH & Co. KG)", 
                    "Bifidobacteri(Live Combined Bifidobacterium\uff0cLactobac and Enterococcus Capsules)", 
                    "(produced by Shanghai XinYi Company)"
                ]
            }, 
            {
                "arm_group_label": "control", 
                "description": "have no any drug", 
                "intervention_name": "control", 
                "intervention_type": "Drug", 
                "other_name": "control"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Pancreatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China"
                }, 
                "name": "Renji Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps", 
        "overall_contact": {
            "email": "txqwl2004@163.com", 
            "last_name": "Xiaoqing Tian"
        }, 
        "overall_official": {
            "affiliation": "RenJi Hospital", 
            "last_name": "Shengliang Chen", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The whole patients need be examined by colonoscopy one year later. The recurrence rate of colon polyps will be acquired in different arms", 
            "measure": "recurrence of colon polyps", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097394"
        }, 
        "responsible_party": {
            "investigator_affiliation": "RenJi Hospital", 
            "investigator_full_name": "Shengliang Chen", 
            "investigator_title": "professor,chief physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "RenJi Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RenJi Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}